Skip to content

Doctors and patients are flying blind as medical marijuana use rises, research lags

July 25, 2019 / Arfinn Med MD /

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to treat health issues like rheumatic and musculoskeletal disease (the aches and pains of arthritis).

Unfortunately, because cannabis remains illegal and classified as a Schedule 1 drugunder federal law (defined as being of no medical use), there has been a troubling lack of scientific and medical research on the effectiveness of cannabis treatments. This dearth of evidence-based data has left many health care providers unable to counsel their patients on everything from whether a cannabis treatment could be effective for their condition, to what dosages are appropriate, to how cannabis might interact with their other medications or health conditions.

Read Full Article Here

Stories you may be interested in

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

Older adults and medical marijuana: Reduced stigma and increased use

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but…
Read More →

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More →

Texas House Bill 3703: What You Need to Know

The state of Texas has been in the news in recent months as the legislature review House Bill 3703. This bill relates to “the prescription of low-THC cannabis for medical use by certain qualified physicians to patients with [specific] qualifying conditions”. Originally filed in March of 2019, this bill made its way through the house…
Read More →

Unstructured EHR data more useful for predictive analytics, study shows

A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More →

Leave a Comment

You must be logged in to post a comment.